Anja Seckinger

Title: Anja Seckinger: Innovator in Bispecific Antibodies

Introduction

Anja Seckinger is a prominent inventor based in Lachen, Switzerland. She has made significant contributions to the field of biomedicine, particularly in the development of bispecific antibodies. With a total of two patents to her name, her work focuses on innovative treatments for malignancies.

Latest Patents

Anja Seckinger's latest patents include groundbreaking inventions such as the Bispecific GPC3xCD28 and GPC3xCD3 antibodies. This invention relates to the use of GPC3×CD3 bispecific antibodies and GPC3×CD28 bispecific antibodies, which are designed for the targeted killing of GPC3 positive malignant cells. The combination of these antibodies offers a novel approach to treating GPC3 positive malignancies. Another significant patent involves bispecific antibodies against CEACAM5 and CD47. This invention encompasses polynucleotides encoding such antibodies, as well as methods for selecting and producing them. The therapeutic applications of these bispecific antibodies extend to both monotherapy and combination therapy.

Career Highlights

Anja has worked with notable companies in the biotechnology sector, including Lamkap Bio Gamma AG and Lamkap Bio Beta Ltd. Her experience in these organizations has contributed to her expertise in antibody development and therapeutic applications.

Collaborations

Anja has collaborated with professionals such as Eric Hatterer and Dirk Hose, enhancing her research and development efforts in the field of bispecific antibodies.

Conclusion

Anja Seckinger is a trailblazer in the development of bispecific antibodies, with her innovative patents paving the way for new treatments in oncology. Her contributions to the field are invaluable and continue to impact the medical community positively.